Cognivue launches CARM, a novel metric predicting amyloid presence and enabling early Alzheimer's detection. The CARM score combines age with cognitive subtests to generate a four-point risk score indicating the likelihood of amyloid presence in the brain.
Scientists from Centre for Ocular Research & Education (CORE) unveiled multiple advancements in 3D printing, accelerating development of drug delivery systems, biodegradable contact lenses, and pharmaceuticals. CORE's innovations include a novel method to fabricate PDMS microfluidic chips with high throughput.
A new peer-reviewed study confirms MiSight 1 day contact lenses slow eye growth and halt myopia progression in 90% of children, with no loss of effectiveness over time. The longest-running soft contact lens study among children demonstrates sustained efficacy for nearly all children, regardless of age or initial refractive error.
A seven-year study by CooperVision indicates that MiSight 1 day contact lenses slow myopia progression without a rebound effect, even after treatment cessation. The lenses demonstrate sustained slowing of myopia progression across different ages and with varying levels of myopia.
CooperVision presented over 20 papers and posters on presbyopia, soft toric lens fitting, and myopia control. The research highlights the importance of patient input, toric lens performance attributes, and children's acceptance of myopia control interventions.
A new study compares axial elongation among children with untreated myopia progression, treated myopes, and emmetropes, revealing that normal eye growth continues as the child ages. The analysis suggests that myopic axial elongation may be superimposed on underlying physiological axial elongation.
New contact lens technologies can diagnose diseases like diabetes and cancer, treat eye conditions, and enhance vision. Integrated circuits will enable intraocular pressure monitoring and retinal imaging for early disease detection.
A six-year study found minimal impact on physiological response in children wearing daily disposable soft contact lenses, affirming their safety for correcting myopia and slowing its progression. The research also highlights the importance of lens fit, material, and patient habits in ensuring successful wear.
A large retrospective review of over 1,000 children found very low complication rates for soft contact lens wear, similar to those in adults. The study's findings offer reassurance to eye care professionals and parents about the safety of myopia management options.
The CooperVision MiSight 1 day clinical study found that nearly one in four children's eyes remain stable for myopia after six years. The study also suggests that commencing treatment at an older age can slow the rate of myopia progression.
A new literature analysis published in Ophthalmic & Physiological Optics provides a comprehensive review of evidence-based information for managing myopia. The paper discusses various safety and efficacy considerations for behavioral, optical, and pharmaceutical pathways, as well as potential future avenues for myopia management.
Ocular scientists provide evidence-based guidance for practitioners and patients on safe use of contact lenses during COVID-19 pandemic, emphasizing importance of good hand hygiene, proper lens care, and temporary lens removal when ill. Experts also debunk rumors about glasses/spectacles providing protection against COVID-19.
The FDA has approved MiSight 1 day, a daily wear contact lens that slows the progression of myopia in children aged 8-12. The lens is the first and only FDA-approved product clinically proven to slow myopia progression.
A four-year study reveals that a contact lens management approach can significantly slow myopia progression in children, including those who start treatment later. The innovative miSight lens has been shown to reduce myopic progression rates by 59% and 52% compared to a control group.
A pioneering contact lens therapy has shown considerable potential to impact the rising prevalence of myopia in children, slowing its progression by 59%. The dual-focus contact lens was effective in reducing the rate of juvenile-onset myopia, with no side effects common to alternative pharmacological therapies.
A groundbreaking contact lens therapy has been shown to be effective in slowing the progression of myopia in children, with a significant reduction in refractive error and axial length. The study also found high satisfaction rates among both children and parents, with rapid acceptance of contact lens wear.